Stock Track | Tandem Diabetes Care Plunges 12.62% After-Hours on Disappointing Q4 Results

Stock Track

Feb 27, 2025

Tandem Diabetes Care's stock experienced a significant after-hours plunge of 12.62% on Wednesday, following the release of the company's fourth-quarter and full-year 2024 financial results.

The company reported an adjusted operating loss of $30.2 million for Q4, missing analysts' estimates of a $17.6 million loss. Additionally, the adjusted net loss for the quarter came in at $28.8 million, wider than the consensus estimate of a $14.9 million loss.

Despite the disappointing financial results, analysts at Wells Fargo maintained their "Buy" rating on Tandem Diabetes Care, citing the company's positioning for growth with the recent FDA approval of its Control IQ+ technology. However, the market reacted negatively to the weaker-than-expected earnings, leading to the significant after-hours stock price decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1103090550"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1103090550\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1103090550?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 05:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103090550","market":"hk","top_or_hot":-1,"title":"Stock Track | Tandem Diabetes Care Plunges 12.62% After-Hours on Disappointing Q4 Results","media":"Stock Track","content":"<p>Tandem Diabetes Care's stock experienced a significant after-hours plunge of 12.62% on Wednesday, following the release of the company's fourth-quarter and full-year 2024 financial results.</p>\n\n<p>The company reported an adjusted operating loss of $30.2 million for Q4, missing analysts' estimates of a $17.6 million loss. Additionally, the adjusted net loss for the quarter came in at $28.8 million, wider than the consensus estimate of a $14.9 million loss.</p>\n\n<p>Despite the disappointing financial results, analysts at Wells Fargo maintained their \"Buy\" rating on Tandem Diabetes Care, citing the company's positioning for growth with the recent FDA approval of its Control IQ+ technology. However, the market reacted negatively to the weaker-than-expected earnings, leading to the significant after-hours stock price decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tandem Diabetes Care Plunges 12.62% After-Hours on Disappointing Q4 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tandem Diabetes Care Plunges 12.62% After-Hours on Disappointing Q4 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-27 05:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tandem Diabetes Care's stock experienced a significant after-hours plunge of 12.62% on Wednesday, following the release of the company's fourth-quarter and full-year 2024 financial results.</p>\n\n<p>The company reported an adjusted operating loss of $30.2 million for Q4, missing analysts' estimates of a $17.6 million loss. Additionally, the adjusted net loss for the quarter came in at $28.8 million, wider than the consensus estimate of a $14.9 million loss.</p>\n\n<p>Despite the disappointing financial results, analysts at Wells Fargo maintained their \"Buy\" rating on Tandem Diabetes Care, citing the company's positioning for growth with the recent FDA approval of its Control IQ+ technology. However, the market reacted negatively to the weaker-than-expected earnings, leading to the significant after-hours stock price decline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNDM","symbol_name":"Tandem Diabetes","start_time":0,"source_url":"","article_id":"1103090550","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103090550","pubTimestamp":1740605731,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Tandem Diabetes Care's stock experienced a significant after-hours plunge of 12.62% on Wednesday, following the release of the company's fourth-quarter and full-year 2024 financial results.The company reported an adjusted operating loss of $30.2 million for Q4, missing analysts' estimates of a $17.6 million loss. Additionally, the adjusted net loss for the quarter came in at $28.8 million, wider than the consensus estimate of a $14.9 million loss.Despite the disappointing financial results, anal","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNDM":"Tandem Diabetes"},"translate_title":"由于第四季度业绩令人失望，Tandem Diabete Care盘后股价暴跌12.62%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNDM":1},"content_text":"Tandem Diabetes Care's stock experienced a significant after-hours plunge of 12.62% on Wednesday, following the release of the company's fourth-quarter and full-year 2024 financial results.\nThe company reported an adjusted operating loss of $30.2 million for Q4, missing analysts' estimates of a $17.6 million loss. Additionally, the adjusted net loss for the quarter came in at $28.8 million, wider than the consensus estimate of a $14.9 million loss.\nDespite the disappointing financial results, analysts at Wells Fargo maintained their \"Buy\" rating on Tandem Diabetes Care, citing the company's positioning for growth with the recent FDA approval of its Control IQ+ technology. However, the market reacted negatively to the weaker-than-expected earnings, leading to the significant after-hours stock price decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}